… The membrane dopamine transporter (DAT) has a pivotal role in the regulation of dopamine
(DA) neurotransmission involved in a number of physiological functions and brain disorders. …

… Since then, various positron-emitting radiopharmaceuticals have been developed for PET
… the presynaptic transporters (eg, dopamine and serotonin). These radiopharmaceuticals are …

… SPECT systems are less expensive than PET systems, and that costs for the production of
SPECT radiopharmaceuticals are lower than PET radiopharmaceuticals. This gap, however, …

… to DA; (2) agents imaging the dopamine transporters (DAT) that are located at the extracellular
… , and (3) agents imaging vesicular monoamine transporter type 2 (VMAT2) located on the …

… dopamine transporter and that pretreatment with drugs that bind to the dopamine transporter
can completely in hibit its specific binding (40). Also, its kinetics are ideally suited to the …

… by a cyclotron based radiopharmacy. Fluorine-18 is also the lowest energy positron emitter
(0.635 MeV, 2.4 mm positron range) and affords the highest PET resolution images. Thus, the …

… The dopamine transporter (DAT) has attracted the attention of neuro-researchers due to its
involvement in many neurodegenerative and psychiatric diseases; amongst these Parkinson’…

… through the dopamine reuptake site (dopamine transporter, DAT). Otherwise, dopamine may
… By administration of radiopharmaceuticals, PET uses naturally occurring radionuclides that …

… dopamine transporter (DAT) is involved in a number of brain disorders and its exploration by
positron emission tomography (PET) … a suitable radiopharmaceutical for PET assessment of …

… a new generation of highly selective dopamine transporter (DAT) ligands (KD: 9 nM for the
DAT and IC50 > 1000 nM for the serotonin and norepinephrine transporter). Initial fluorine-18-…